Pipeline/Trials

Our commitment to excellence

Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.

Program

Drug candidate

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

Orascovery
(P-gp inhibitor [encequidar] + ChemoRx agents)

Metastatic breast cancer

Angiosarcoma

Oral topotecan + encequidar

Solid tumors

Oral eribulin + encequidar

Solid tumors

Dual Inhibition

ATNX-04 (CYP/P-gp)

Multiple tumors

Src Kinase Inhibition

Tirbanibulin (KX2-391) ointment

Actinic keratosis

Psoriasis

Skin cancers

Tirbanibulin (KX2-391) oral

Liquid tumors

Ovarian cancer

KX2-361 (KX-02)

Glioblastoma

TCR-T Immunotherapy

TAEST16001

Multiple tumors

Arginine Deprivation Therapy

(PT-01) Pegtomarginase

Multiple tumors

Posted pipeline was current on January 2, 2020. Pipeline may not reflect changes in phase of development after January 2, 2020.

*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.

Clinical Platform

Orascovery
(P-gp inhibitor [encequidar] + ChemoRx agents)

Oral paclitaxel + encequidar*


Metastatic breast cancer

PHASE 3

Angiosarcoma

PHASE 2
PHASE 1
PHASE 1

Oral topotecan + encequidar


Solid tumors

PHASE 1

Oral eribulin + encequidar


Solid tumors

PHASE 1

Clinical Platform

Dual Inhibition

ATNX-04 (CYP/P-gp)


Multiple tumors

PRE-CLINICAL

Clinical Platform

Src Kinase Inhibition

Tirbanibulin (KX2-391) ointment


Actinic keratosis

PHASE 3

Psoriasis

PHASE 1

Skin cancers

PRE-CLINICAL

Tirbanibulin (KX2-391) oral


Liquid tumors

PHASE 1

Ovarian cancer

PRE-CLINICAL

KX2-361 (KX-02)


Glioblastoma

PHASE 1

Clinical Platform

TCR-T Immunotherapy

TAEST16001


Multiple tumors

PRE-CLINICAL

Clinical Platform

Arginine Deprivation Therapy

(PT-01) Pegtomarginase


Multiple tumors

PRE-CLINICAL

Posted pipeline was current on January 2, 2020. Pipeline may not reflect changes in phase of development after January 2, 2020.

*Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
**Collaboration with Eli Lilly and Company, makers of ramucirumab.